The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography

Cancer J. May-Jun 2002;8(3):222-33. doi: 10.1097/00130404-200205000-00003.

Abstract

Purpose: We reviewed the current literature to discover the range of studies covering tissue-based and noninvasive methods for determining tumor stage and the prognostic value of staging in non-small cell lung cancer.

Design: Despite refinements in staging of non-small cell lung cancer, each stage remains heterogeneous because each stage contains patients who are at higher risk for recurrence than other patients within the same stage. Tissue-based and noninvasive methods have been investigated to complement tumor stage in assessing non-small cell lung cancer prognosis. The prognostic significance of tumor proliferation assessed by Ki-67 protein expression has been demonstrated in non-small cell lung cancer.

Result: Recent positron emission tomography studies have also shown both prognostic value in non-small cell lung cancer uptake of [F-18] fluorodeoxyglucose (FDG) and correlation between non-small cell lung cancer FDG uptake and tumor proliferation.

Discussion: We reviewed the prognostic significance of Ki-67 expression in non-small cell lung cancer and related it to positron emission tomography.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antigens, Neoplasm / analysis*
  • Carcinoma, Non-Small-Cell Lung / chemistry
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Fluorodeoxyglucose F18
  • Humans
  • Ki-67 Antigen / analysis*
  • Lung Neoplasms / chemistry
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / pathology
  • Lymphatic Metastasis / diagnostic imaging
  • Neoplasm Staging
  • Prognosis
  • Radiopharmaceuticals
  • Tomography, Emission-Computed / methods

Substances

  • Antigens, Neoplasm
  • Ki-67 Antigen
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18